BTIG raised the firm’s price target on iRhythm (IRTC) to $215 from $195 and keeps a Buy rating on the shares. The company reported another stellar quarter, with revenue accelerating to $192.9M, up 30.7% y/y, while the $8M beat to consensus was driven by a record quarter from both Zio Monitor and Zio AT as IRTC expanded in the PCP channel, increased proactive monitoring penetration at new innovative channel partners, and continued to integrate Zio into EHRs, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $242 from $205 at Citi
- iRhythm price target raised to $212 from $193 at Canaccord
- Irhythm Technologies: Strong Q3 Performance and Positive Outlook Justify Buy Rating
- Irhythm Technologies: Strong Performance and Promising Growth Potential Justify Buy Rating
- iRhythm Technologies: Strong Growth and Strategic Initiatives Justify Buy Rating